Advertisement

The involvement of ventral hippocampal microglial cells, but not cannabinoid CB1 receptors, in morphine-induced analgesia in rats

  • Hanieh Javid
  • Ameneh RezayofEmail author
  • Zahra Ghasemzadeh
  • Maryam Sardari
Original article

Abstract

It is well known that glial cells are involved in pain processing. The purpose of the present study was to investigate the possible involvement of the ventral hippocampal (VH) glial cells in morphine-induced analgesia. A tail-flick apparatus was used to measure pain sensitivity in male Wistar rats that were bilaterally cannulated in the VH by stereotaxic surgery. The results showed that intraperitoneal (i.p.) administration of morphine (2.5–7.5 mg/kg) induced analgesia in a time-dependent manner. The blockade of the VH glial cell activation by bilateral microinjection of a glial inhibitor, minocycline (5–15 µg/rat) into the VH with an ineffective dose of morphine (2.5 mg/kg, i.p) significantly increased morphine analgesia. Considering that the endocannabinoid system via CB1 receptors play a crucial role in pain modulation, we also assessed the possible role of the VH cannabinoid CB1 receptors in the functional interaction between minocycline and morphine in acute pain. Our results indicated that intra-VH injection of the cannabinoid CB1 receptor agonist, arachidonylcyclopropylamide (ACPA; 4–12 ng/rat) had no effect on minocycline-induced potentiation of morphine analgesia. It should be considered that intra-VH microinjection of minocycline or ACPA by itself had no effect on tail-flick latency. Our findings suggest that the activation of the VH microglial cells may be involved in mediating pain sensation, because the inhibition of these cells by intra-VH injection of minocycline could potentiate morphine-induced analgesia. Although endocannabinoids have a regulatory role in glia function, the activation of CB1 receptors could not affect the potentiative effect of minocycline on morphine analgesia.

Keywords

Morphine Minocycline ACPA Ventral hippocampus Analgesia Rat(s) 

Abbreviations

ACPA

Arachidonylcyclopropylamide

ANOVA

Analysis of variance

AUC

Area under the curve

CB

Cannabinoid

eCBs

Endocannabinoids

i.p.

Intraperitoneal

LTP

Long-term potentiation

MAPKs

Mitogen-associated protein kinases

MPE

Maximum possible effect

SEM

Standard error of mean

TFL

Tail-flick latency

VH

Ventral hippocampus

WIN55,212-2

WIN55,212-2 mesylate

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare.

References

  1. 1.
    Luger NM, Sabino MA, Schwei MJ, Mach DB, Pomonis JD, Keyser CP, Rathbun M, Clohisy DR, Honore P, Yaksh TL, Mantyh PW (2002) Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 99:397–406CrossRefGoogle Scholar
  2. 2.
    Morgan MM, Christie MJ (2011) Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br J Pharmacol 164:1322–1334CrossRefGoogle Scholar
  3. 3.
    Al-Hasani R, Bruchas MR (2011) Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 115:1363–1381Google Scholar
  4. 4.
    Chao CC, Gekker G, Sheng WS, Hu S, Tsang M, Peterson PK (1994) Priming effect of morphine on the production of tumor necrosis factor-alpha by microglia: implications in respiratory burst activity and human immunodeficiency virus-1 expression. J Pharmacol Exp Ther 269:198–203Google Scholar
  5. 5.
    Liang Y, Chu H, Jiang Y, Yuan L (2016) Morphine enhances IL-1β release through toll-like receptor 4-mediated endocytic pathway in microglia. Purinergic Signalling 12(4):637–645CrossRefGoogle Scholar
  6. 6.
    Gosselin RD, Suter MR, Ji RR, Decosterd I (2010) Glial cells and chronic pain. Neuroscientist 16:519–531CrossRefGoogle Scholar
  7. 7.
    Hutchinson MR, Northcutt AL, Chao LW, Kearney JJ, Zhang Y, Berkelhammer DL, Loram LC, Rozeske RR, Bland ST, Maier SF, Gleeson TT, Watkins LR (2008) Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun 22:1248–1256CrossRefGoogle Scholar
  8. 8.
    Ghazvini H, Rezayof A, Ghasemzadeh Z, Zarrindast MR (2015) μ-Opioid and N-methyl-d-aspartate receptors in the amygdala contribute to minocycline-induced potentiation of morphine analgesia in rats. Behav Pharmacol 26:383–392CrossRefGoogle Scholar
  9. 9.
    Kosarmadar N, Ghasemzadeh Z, Rezayof A (2015) Inhibition of microglia in the basolateral amygdala enhanced morphine-induced analgesia: possible role of GABAA receptors. Eur J Pharmacol 765:157–163CrossRefGoogle Scholar
  10. 10.
    Mika J, Osikowicz M, Makuch W, Przewlocka B (2007) Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 560:142–149CrossRefGoogle Scholar
  11. 11.
    Cui Y, Liao XX, Liu W, Guo RX, Wu ZZ, Zhao CM, Chen PX, Feng JQ (2008) A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav Immun 22:114–123CrossRefGoogle Scholar
  12. 12.
    Clayton N, Marshall FH, Bountra C, O’Shaughnessy CT (2002) CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96:253–260CrossRefGoogle Scholar
  13. 13.
    Fang Q, Han ZL, Li N, Wang ZL, He N, Wang R (2012) Effects of neuropeptide FF system on CB1 and CB2 receptors mediated antinociception in mice. Neuropharmacology 62:855–864CrossRefGoogle Scholar
  14. 14.
    Stella N (2009) Endocannabinoid signaling in microglial cells. Neuropharmacology 56:244–253CrossRefGoogle Scholar
  15. 15.
    Nadal X, La Porta C, Andreea Bura S, Maldonado R (2013) Involvement of the opioid and cannabinoid systems in pain control: new insights from knockout studies. Eur J Pharmacol 716:142–157CrossRefGoogle Scholar
  16. 16.
    Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, Pfister SL, Campbell WB, Hillard CJ (2004) Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 65:999–1007CrossRefGoogle Scholar
  17. 17.
    Viader A, Blankman JL, Zhong P, Liu X, Schlosburg JE, Joslyn CM, Liu QS, Tomarchio AJ, Lichtman AH, Selley DE, Sim-Selley LJ, Cravatt BF (2015) Metabolic interplay between astrocytes and neurons regulates endocannabinoid action. Cell Rep 12:798–808CrossRefGoogle Scholar
  18. 18.
    Lisboa SF, Gomes FV, Guimaraes FS, Campos AC (2016) Microglial cells as a link between cannabinoids and the immune hypothesis of psychiatric disorders. Front Neurol 7:5CrossRefGoogle Scholar
  19. 19.
    Lopez-Rodriguez AB, Siopi E, Finn DP, Marchand-Leroux C, Garcia-Segura LM, Jafarian-Tehrani M, Viveros MP (2015) CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. Cereb Cortex 25:35–45CrossRefGoogle Scholar
  20. 20.
    Basbaum AI, Fields HL (1984) Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 7:309–338CrossRefGoogle Scholar
  21. 21.
    Liu MG, Chen J (2009) Roles of the hippocampal formation in pain information processing. Neurosci Bull 25:237–266CrossRefGoogle Scholar
  22. 22.
    Nasehi M, Kafi F, Khakpai F, Zarrindast MR (2015) Involvement of the serotonergic system of the ventral hippocampus (CA3) on amnesia induced by ACPA in mice. Behav Brain Res 286:356–363CrossRefGoogle Scholar
  23. 23.
    Nasehi M, Kafi F, Zarrindast MR (2013) Differential mechanisms of opioidergic and dopaminergic systems of the ventral hippocampus (CA3) in anxiolytic-like behaviors induced by cholestasis in mice. Eur J Pharmacol 714:352–358CrossRefGoogle Scholar
  24. 24.
    Al-Amin HA, Atweh SF, Jabbur SJ, Saadé NE (2004) Effects of ventral hippocampal lesion on thermal and mechanical nociception in neonates and adult rats. Eur J Neurosci 20:3027–3034CrossRefGoogle Scholar
  25. 25.
    Rea K, Ford GK, Olango WM, Harhen B, Roche M, Finn DP (2014) Microinjection of 2-arachidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state. Eur J Neurosci 39:435–443CrossRefGoogle Scholar
  26. 26.
    Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168:299–325CrossRefGoogle Scholar
  27. 27.
    Arvidsson U, Riedl M, Chakrabarti S, Lee JH, Nakano AH, Dado RJ, Loh HH, Law PY, Wessendorf MW, Elde R (1995) Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci 15:3328–3341CrossRefGoogle Scholar
  28. 28.
    Bushlin I, Rozenfeld R, Devi LA (2010) Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol 10:80–86CrossRefGoogle Scholar
  29. 29.
    Zimmerman ME, Pan JW, Hetherington HP, Lipton ML, Baigi K, Lipton RB (2009) Hippocampal correlates of pain in healthy elderly adults: a pilot study. Neurology 73:1567–1570CrossRefGoogle Scholar
  30. 30.
    Doyle HH, Eidson LN, Sinkiewicz DM, Murphy AZ (2017) Sex differences in microglia activity within the periaqueductal gray of the rat: a potential mechanism driving the dimorphic effects of morphine. J Neurosci 37:3202–3214CrossRefGoogle Scholar
  31. 31.
    Ryu JK, Franciosi S, Sattayaprasert P, Kim SU, McLarnon JG (2004) Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia 48:85–90CrossRefGoogle Scholar
  32. 32.
    Taves S, Berta T, Chen G, Ji RR (2013) Microglia and spinal cord synaptic plasticity in persistent pain. Neural Plast 2013:753656CrossRefGoogle Scholar
  33. 33.
    Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates, 3rd edn. Academic Press, San DiegoGoogle Scholar
  34. 34.
    Wilson RP, Zagon IS, Larach DR, Lang CM (1992) Antinociceptive properties of tiletamine-zolazepam improved by addition of xylazine or butorphanol. Pharmacol Biochem Behav 43:1129–1133CrossRefGoogle Scholar
  35. 35.
    Ness TJ, Jones SL, Gebhart GF (1987) Contribution of the site of heating to variability in the latency of the rat tail flick reflex. Brain Res 426:169–172CrossRefGoogle Scholar
  36. 36.
    Zhang X, Bao L, Li S (2015) Opioid receptor trafficking and interaction in nociceptors. Br J Pharmacol 172:364–374CrossRefGoogle Scholar
  37. 37.
    Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR (1997) Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94:1544–1549CrossRefGoogle Scholar
  38. 38.
    Han Y, Jiang C, Tang J, Wang C, Wu P, Zhang G, Liu W, Jamangulova N, Wu X, Song X (2014) Resveratrol reduces morphine tolerance by inhibiting microglial activation via AMPK signalling. Eur J Pain 18:1458–1470CrossRefGoogle Scholar
  39. 39.
    Auvity S, Saba W, Goutal S, Leroy C, Buvat I, Cayla J, Caillé F, Bottlaender M, Cisternino S, Tournier N (2016) Acute morphine exposure increases the brain distribution of [18f]dpa-714, a pet biomarker of glial activation in nonhuman primates. Int J Neuropsychopharmacol 19:67–71Google Scholar
  40. 40.
    Macey TA, Lowe JD, Chavkin C (2006) Mu opioid receptor activation of ERK1/2 is GRK3 and arrestin dependent in striatal neurons. J Biol Chem 281:34515–34524CrossRefGoogle Scholar
  41. 41.
    Nikodemova M, Duncan ID, Watters JJ (2006) Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J Neurochem 96:314–323CrossRefGoogle Scholar
  42. 42.
    Zhu J, Wei X, Liu J, Hu Y, Xu J (2009) Interaction of glia activation and neurotransmission in hippocampus of neuropathic rats treated with mirtazapine. Exp Clin Psychopharmacol 17:198–203CrossRefGoogle Scholar
  43. 43.
    Duric V, McCarson KE (2006) Persistent pain produces stress-like alterations in hippocampal neurogenesis and gene expression. J Pain 7:544–555CrossRefGoogle Scholar
  44. 44.
    Kodama D, Ono H, Tanabe M (2007) Altered hippocampal long-term potentiation after peripheral nerve injury in mice. Eur J Pharmacol 574:127–132CrossRefGoogle Scholar
  45. 45.
    Wilson AR, Maher L, Morgan MM (2008) Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine analgesia. Neuropharmacology 55:1219–1225CrossRefGoogle Scholar
  46. 46.
    Smith PA, Selley DE, Sim-Selley LJ, Welch SP (2007) Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 571:129–137CrossRefGoogle Scholar
  47. 47.
    Burgos E, Gomez-Nicola D, Pascual D, Martín MI, Nieto-Sampedro M, Goicoechea C (2012) Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells. Eur J Pharmacol 682:62–72CrossRefGoogle Scholar
  48. 48.
    Rashidy-Pour A, Pahlevani P, Vaziri A, Shaigani P, Zarepour L, Vafaei AA, Haghparast A (2013) Involvement of CB1 receptors in the ventral tegmental area in the potentiation of morphine rewarding properties in acquisition but not expression in the conditioned place preference model. Behav Brain Res 247:259–267CrossRefGoogle Scholar
  49. 49.
    Molaei M, Fatahi Z, Zaringhalam J, Haghparast A (2016) CB1 cannabinoid agonist (WIN55,212-2) within the basolateral amygdala induced sensitization to morphine and increased the level of μ-opioid receptor and c-fos in the nucleus accumbens. J Mol Neurosci 58:446–455CrossRefGoogle Scholar
  50. 50.
    Khasabova IA, Gielissen J, Chandiramani A, Harding-Rose C, Odeh DA, Simone DA, Seybold VS (2011) CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. Behav Pharmacol 22:607–616CrossRefGoogle Scholar
  51. 51.
    Rubino T, Realini N, Castiglioni C, Guidali C, Viganó D, Marras E, Petrosino S, Perletti G, Maccarrone M, Di Marzo V, Parolaro D (2008) Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 18:1292–1301CrossRefGoogle Scholar
  52. 52.
    Hájos N, Freund TF (2002) Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 121:73–82CrossRefGoogle Scholar
  53. 53.
    Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG (2008) Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 109:101–110CrossRefGoogle Scholar

Copyright information

© Belgian Neurological Society 2019

Authors and Affiliations

  • Hanieh Javid
    • 1
  • Ameneh Rezayof
    • 1
    Email author
  • Zahra Ghasemzadeh
    • 1
  • Maryam Sardari
    • 1
  1. 1.Department of Animal Biology, School of Biology, College of ScienceUniversity of TehranTehranIran

Personalised recommendations